The biotechnology company Evotec achieved a slight increase in sales last year thanks to a strong fourth quarter.
The operational result collapsed massively, but exceeded the market expectations. The annual forecast was fulfilled. For the 2025 financial year, the company listed in the MDAX and TECDAX promises further growth and a significant improvement in results. Evotec also presented a new strategy for sustainable profitable growth.
In 2024, the group turnover rose by 2 percent to 797.0 million euros and thus met the analyst’s consensus estimate. After a sales minus of 1 percent had been in sales after nine months, the income in the final quarter attracted 10 percent to 221.2 million euros.
The adjusted Group Ebitda amounted to 22.6 million euros, after 66.4 million in the previous year, which was for a mismatch between sales and cost base in the Shared R&D Evotec segment. The segment implemented 9 percent less last year.
Evotec had promised Group sales in the range of 790 to 820 million euros and an adjusted group beitda between 15 and 35 million euros. Analysts had expected sales of 797 million euros and adjusted EBITDA of 17 million euros in the consensus.
Evotec expects consolidated sales of 840 to 880 million euros for 2025 and an adjusted Group Ebitda of 30 to 50 million euros.
Dow Jones
Selected leverage products on Evotec
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Evotec
The lever must be between 2 and 20
Advertising